Aptose reports Q3 net loss $5.1M, cash $1.6M, but TUS+VEN+AZA shows 100% CR/CRh at higher doses

Aptose Biosciences Inc.

2025-Q3 EPS reported -$7.34

Net loss $5.1M (-$2.01/share) for Q3 2025 vs $7.0M (-$11.33/share) in Q3 2024; nine-month net loss $17.7M.
Cash and equivalents $1.6M as of Sep 30, 2025; company states insufficient cash to fund operations, relying on Hanmi advances.
TUS+VEN+AZA triplet: 6/6 (100%) achieved CR/CRh at 80/120 mg TUS doses, exceeding 66% expected from VEN+AZA alone; overall 9/10 (90%) CR/CRh.
Dose escalation to 160 mg TUS underway; updated data to be presented at ASH December 2025.
Shareholders' deficit of $19.5M; company actively pursuing financing and cost reductions.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.